Researchers from MIT are onto a potentially breakthrough approach to make HIV vaccines more effective with a new study suggesting that a two-dose schedule, spaced a week apart, primes the immune system significantly. Previously, a seven-dose regimen over a fortnight had shown promise in boosting neutralizing antibodies against the fast-mutating virus, but its practicability for large-scale vaccination efforts was questionable. The latest findings revealed by MIT indicate that by administering 20 percent of the vaccine in the initial dose followed by 80 percent in the second dose a week later, an equally potent immune response can be triggered.
In an effort to practically re-engineer the previous vaccination strategy, the team, led by Arup Chakraborty and Darrell Irvine along with PhD researchers Sachin Bhagchandani and Leerang Yang, sought to essentially recreate the accumulative immune response generated by multiple exposures to the virus. This two-dose method, as MIT News reports, doesn't only potentially streamline vaccination protocols but also enhances both T-cell and antibody responses—a crucial factor given the virus's ability to evade the immune system through rapid mutation.
Interestingly, the study employed computational modeling alongside animal experiments to refine the dosage timetable. The groundbreaking finding was that the first dose doesn't need to significantly generate antibodies in large amounts but instead sets the stage for the second dose. Administration of a much smaller initial dose preps the immune system without wasting antigen and allows for a larger, more protective dose to follow. "The early doses generate some small amounts of antibody, and that’s enough to then bind to the vaccine of the later doses, protect it, and target it to the lymph node," Bhagchandani told MIT News.
According to their research, when the immune system is primed with the first dose, the second dose delivers a powerful boost, considerably improving the population of B cells responsible for targeting the virus. It further emerged that this schedule induces not only a strong antibody response—60 times better compared to a single dose—but also a quintupled improvement in the T-cell response. "Reducing the ‘escalating dose’ strategy down to two shots makes it much more practical for clinical implementation," Irvine remarked in a discussion with MIT News. Irvine also hinted at ongoing developments that could, in time, allow for these two doses to be merged into a single shot ideal for mass vaccination drives.
While the initial findings are promising, further studies are underway in a nonhuman primate model, with the MIT team also exploring materials that could enable prolonged delivery of the second dose. This innovative approach, supported by funding from various institutes and organizations including the National Institutes of Health, not only represents a strategic advancement in HIV vaccine development but also has the potential to influence vaccine strategies for other infectious diseases.
